Amyloidosis trials in Germany

In Germany 33 Also abroad 184

33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Essen Amyloidosis Registry
Where
Essen
Age
18 years and over
People
400
Run by
University Hospital, Essen
See details and how to joinNCT06887283
Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Berlin, Essen, Heidelberg, Munich, Wuerzburg
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
No phaseTaking people
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Where
Bonn, München
Age
18 years and over
People
2,200 worldwide
Run by
Idoven 1903 S.L.
See details and how to joinNCT06978660
No phaseNot yet taking people in Germany
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor
Where
Heidelberg
Age
18 years and over
People
60 worldwide
Run by
Bayer
See details and how to joinNCT07557147
Phase 3Taking people
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Where
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel, München, Munich, Münster, Würzburg
Age
18 years and over
People
1,280 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07207811
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Berlin, Cologne, Dresden, Erlangen, Goettingen, Hanover, Heidelberg, Leipzig, Magdeburg, Muenster, Munich, Wuerzburg
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
Edge-to-edge Mitral Valve Repair in ATTR-CM
Where
Hanover, Heidelberg, München
Age
18 years and over
People
106 worldwide
Run by
Medical University of Vienna
See details and how to joinNCT06075823
Phase 4Taking people
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
Where
Berlin, Bonn, Darmstadt, Greifswald, Hamburg, Ulm
Age
18 years to 90 years
People
50 worldwide
Run by
Bayer
See details and how to joinNCT07298044 · EU 2025-521831-35-00
No phaseTaking people
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Where
Berlin, Giessen, Hanover
People
1,500 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT04561518
No phaseTaking people
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Where
Heidelberg, Munich, Münster, Würzburg
Age
18 years and over
People
2,000 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07358078
No phaseTaking people
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Where
Münster
People
10 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT05040373
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Berlin, Heidelberg, Muenster
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Where
Multiple Locations
Age
18 years and over
People
2,000 worldwide
Run by
Bayer
See details and how to joinNCT07235462
No phaseTaking people
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Where
Aachen, Berlin, Cologne, Frankfurt am Main, Hanover, Homburg, Mainz, Würzburg
Age
18 years to 130 years
People
1,850 worldwide
Run by
AstraZeneca
See details and how to joinNCT06465810
No phaseTaking people
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Where
Hanover
Age
18 years and over
People
320 worldwide
Run by
AstraZeneca
See details and how to joinNCT07654855
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Berlin
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
No phaseTaking people
Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR)
Where
Tübingen
Age
18 years and over
People
600
Run by
University Hospital Tuebingen
See details and how to joinNCT07752732
Phase 3Not yet taking people in Germany
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Where
Berlin, Cologne, Essen, Gie En, Hamburg, Hanover, Heidelberg, Homburg, Kiel, Leipzig, M Nchen, Münster, W Rzburg
People
1,180 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00
No phaseTaking people
The Eplontersen Pregnancy and Lactation Outcomes Study
Where
Frankfurt
People
10
Run by
AstraZeneca
See details and how to joinNCT07205666
No phaseTaking people
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
Where
Berlin, Essen, Frankfurt am Main, Würzburg
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07690436
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
Berlin, Essen, Heidelberg, Wuerzburg
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 3Not yet taking people in Germany
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Where
Berlin, Heidelberg, Mainz
Age
18 years and over
People
250 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Berlin, Heidelberg, Mainz
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
No phaseNot yet taking people in Germany
Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis
Where
Düsseldorf
Age
18 years and over
People
200
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT07577466
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Cologne, Heidelberg, Homburg, Münster, Würzburg
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493